DV
Dividend Vision

IRON — Disc Medicine, Inc.

Disc Medicine, Inc. (IRON)

Total return is -74.5% over the past 6 years, 224.3 points behind SPY at 149.8%. Its deepest 1-year drawdown was 40.5%.

Disc Medicine is a clinical-stage biopharmaceutical company developing novel treatments for serious hematologic diseases, with a pipeline focused on modifying biological pathways related to red blood cell formation and iron metabolism. The company's lead programs include bitopertin for erythropoietic porphyrias, DISC-0974 for anemia in myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera. As an early-stage biotech company, it does not currently distribute dividends and appeals primarily to growth-oriented investors willing to accept the significant risk inherent in clinical-stage drug development.

IRON key facts

Asset type
Stock
Asset class
Equity
Inception date
08/12/2020
Distribution frequency
None
Last close
$78.84
Market cap
$3,026,891,776
Average volume
262500.0
Beta
2.057
Payout ratio
0.0
Forward P/E
0.0
EPS
$-6.59